CAJ | 학술논문

目的：探讨周期蛋白依赖激酶-2（cyclin dependent kinase 2，CDK2）阳性表达对乳腺癌新辅助化疗疗效的判断价值。方法应用MaxVinsion免疫组织化学技术，检测55例乳腺浸润性导管癌患者中CDK2表达情况。结果55例乳腺浸润性导管癌CDK2阳性表达率为70．9％，CDK2阳性表达率与其临床病理特征（年龄、肿瘤大小及腋窝淋巴结转移）无相关性，并且CDK2阳性表达率与雌激素（ estrogen receptor ， ER）、孕激素（ progesterone receptor ，PR）、细胞表皮生长因子2（cell epidermal growth factor ，CerBb-2）水平也无相关性，CDK2阳性表达率与乳腺癌组织学分级显著相关。39例CDK2阳性患者新辅助化疗总缓解率为61．5％，16例CDK2阴性患者新辅助化疗总缓解率为25．0％，两者总缓解率比较差异具有显著性意义。结论 CDK2表达可预测乳腺浸润性导管癌患者新辅助化疗的疗效。
목적：탐토주기단백의뢰격매-2（cyclin dependent kinase 2，CDK2）양성표체대유선암신보조화료료효적판단개치。방법응용MaxVinsion면역조직화학기술，검측55례유선침윤성도관암환자중CDK2표체정황。결과55례유선침윤성도관암CDK2양성표체솔위70．9％，CDK2양성표체솔여기림상병리특정（년령、종류대소급액와림파결전이）무상관성，병차CDK2양성표체솔여자격소（ estrogen receptor ， ER）、잉격소（ progesterone receptor ，PR）、세포표피생장인자2（cell epidermal growth factor ，CerBb-2）수평야무상관성，CDK2양성표체솔여유선암조직학분급현저상관。39례CDK2양성환자신보조화료총완해솔위61．5％，16례CDK2음성환자신보조화료총완해솔위25．0％，량자총완해솔비교차이구유현저성의의。결론 CDK2표체가예측유선침윤성도관암환자신보조화료적료효。
Objective To explore the value of positive expression of CDK 2 on efficacy of neoadjuvant chemotherapy in breast cancer .Methods The expression of CDK2 in 55 patients with infiltrating ductal carcinoma treated with neoadjuvant chem-otherapy were detected by MaxVinsion immunohistochemical techniques .Results The positive expression rate of CDK 2 in 55 pa-tients with infiltrating ductal carcinoma was 70.9%,it was not related to clinicopathological characteristics ( age,tumor size and axillary lymph node metastasis),and it was not related to ER,PR,CerBb-2 levels.The positive expression rate of CDK2 was relat-ed to histological grading .The effective rate of neoadjuvant chemotherapy in 39 patients with CDK2 positive expression was 61.5%,The effective rate of neoadjuvant chemotherapy in 16 cases of CDK2 negative expression was 25.0%,There had signifi-cant difference .Conclusion CDK2 can predict the efficacy of invasive ductal breast cancer patients treated with neoadjuvant chemotherapy .